Literature DB >> 33587944

Low specificity of point-of-care circulating cathodic antigen (POCCCA) diagnostic test in a non-endemic area for schistosomiasis mansoni in Brazil.

Carlos Graeff-Teixeira1, Vivian Favero2, Vanessa Fey Pascoal2, Renata Perotto de Souza3, Francine de Vargas Rigo2, Luize Hoffmann Dall Agnese2, Fernando Schemelzer Moraes Bezerra4, Paulo Marcos Zech Coelho5, Martin Johannes Enk6, Tereza Cristina Favre7, Naftale Katz8, Ricardo Riccio Oliveira9, Mitermayer Galvão Dos Reis10, Otavio Sarmento Pieri11.   

Abstract

A point-of-care test for detecting schistosome circulating cathodic antigen in urine (POCCCA) has been proposed for mapping infection and defining prevalence thresholds for mass drug administration (MDA). However, there is increasing evidence that POCCCA may yield false-positive results, which requires rigorous specificity evaluation in non-endemic areas. POCCCA was applied in an area known to be free from infection and devoid of any condition for schistosomiasis transmission as part of a multicentre study to evaluate the performance of POCCCA in Brazil's low or potentially endemic settings. Besides POCCCA detection in urine, a search for eggs in stool was performed by Kato-Katz (KK) and Helmintex (HTX) methods. One-hundred-and-seventy-four participants returned urine samples, 140 of which delivered stool samples. All these were HTX-negative for Schistosoma mansoni, and all 118 tested with KK were negative for both S. mansoni and soil-transmitted helminths. POCCCA results from freshly collected urine yielded a specificity of 62.1% (95% CI: 53.6% - 70.2%), taking trace outcomes as positive according to the manufacturer's instructions. Retesting urine from the 140 HTX-negatives after one-year storage at -20 °C with two new POCCCA batches simultaneously yielded significantly different specificities (34.3%; 95%CI: 26.5% - 42.8% and 75.0%; 95% CI: 67.0% - 81.9%). These two batches had a weak agreement (Cohen's kappa: 0.56; 95%CI: 0.44-0.68) among the 174 urine samples retested. At present, POCCCA cannot be recommended either as a cut-off point for MDA or a reliable diagnostic tool for treatment of the infection carriers (selective chemotherapy) in low endemic areas and at final stages of transmission interruption. Manufacturers should be required to optimize production standardization and to assure quality and reproducibility of the test. Extended rigorous performance evaluations by different users from different regions are needed before POCCCA is widely recommended.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brazil; Circulating cathodic antigen (POC-CCA); Helmintex; Kato-Katz; Schistosoma mansoni

Mesh:

Substances:

Year:  2021        PMID: 33587944     DOI: 10.1016/j.actatropica.2021.105863

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  8 in total

1.  Performance of a rapid immuno-chromatographic test (Schistosoma ICT IgG-IgM) for detecting Schistosoma-specific antibodies in sera of endemic and non-endemic populations.

Authors:  Julie Hoermann; Esther Kuenzli; Carmen Schaefer; Daniel H Paris; Silja Bühler; Peter Odermatt; Somphou Sayasone; Andreas Neumayr; Beatrice Nickel
Journal:  PLoS Negl Trop Dis       Date:  2022-05-27

2.  Translating From Egg- to Antigen-Based Indicators for Schistosoma mansoni Elimination Targets: A Bayesian Latent Class Analysis Study.

Authors:  Jessica Clark; Arinaitwe Moses; Andrina Nankasi; Christina L Faust; Moses Adriko; Diana Ajambo; Fred Besigye; Arron Atuhaire; Aidah Wamboko; Candia Rowel; Lauren V Carruthers; Rachel Francoeur; Edridah M Tukahebwa; Poppy H L Lamberton; Joaquin M Prada
Journal:  Front Trop Dis       Date:  2022-02-18

3.  Assessment of periportal fibrosis in Schistosomiasis mansoni patients by proton nuclear magnetic resonance-based metabonomics models.

Authors:  Milena Lima Rodrigues; Tatiane Priscila Santos Rodrigues da Luz; Caroline Louise Diniz Pereira; Andrea Dória Batista; Ana Lúcia Coutinho Domingues; Ricardo Oliveira Silva; Edmundo Pessoa Lopes
Journal:  World J Hepatol       Date:  2022-04-27

4.  Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children.

Authors:  Marta G Cavalcanti; Délia Celser Engel; Aline Fernandes de Araujo Cunha; José Mauro Peralta
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

5.  Evaluation of the Point-of-Care Circulating Cathodic Antigen Assay for Monitoring Mass Drug Administration in a Schistosoma mansoni Control Program in Western Kenya.

Authors:  Anne Straily; Emmy A Kavere; Dollycate Wanja; Ryan E Wiegand; Susan P Montgomery; Alex Mwaki; Alie Eleveld; W Evan Secor; Maurice R Odiere
Journal:  Am J Trop Med Hyg       Date:  2021-11-08       Impact factor: 3.707

6.  Reliability of point-of-care circulating cathodic antigen assay for diagnosing schistosomiasis mansoni in urine samples from an endemic area of Brazil after one year of storage at -20 degrees Celsius.

Authors:  Tereza Cristina Favre; Lilian Christina Nóbrega Holsback Beck; Fernando Schemelzer Moraes Bezerra; Carlos Graeff-Teixeira; Paulo Marcos Zech Coelho; Martin Johannes Enk; Naftale Katz; Ricardo Riccio Oliveira; Mitermayer Galvão Dos Reis; Otávio Sarmento Pieri
Journal:  Rev Soc Bras Med Trop       Date:  2022-02-25       Impact factor: 1.581

7.  Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data.

Authors:  Martin Walker; Luzia T Freitas; Julia B Halder; Matthew Brack; Jennifer Keiser; Charles H King; Bruno Levecke; Yvonne Ai-Lian Lim; Otavio Pieri; Doudou Sow; J Russell Stothard; Joanne P Webster; Xiao-Nong Zhou; Robert F Terry; Philippe J Guérin; Maria-Gloria Basáñez
Journal:  Wellcome Open Res       Date:  2022-01-05

8.  Diagnostic Performance of Parasitological, Immunological, Molecular, and Ultrasonographic Tests in Diagnosing Intestinal Schistosomiasis in Fieldworkers From Endemic Municipalities in the Philippines.

Authors:  Ian Kim B Tabios; Marcello Otake Sato; Ourlad Alzeus G Tantengco; Raffy Jay C Fornillos; Masashi Kirinoki; Megumi Sato; Raniv D Rojo; Ian Kendrich C Fontanilla; Yuichi Chigusa; Paul Mark B Medina; Mihoko Kikuchi; Lydia R Leonardo
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.